Summary

Other Scenarios:

Buyer: ICOS Corporation (ICOS) Last Price: 33.98 Market Cap.: 2.23B
Target: OSI Pharmaceuticals, Inc. (OSIP) Last Price: 33.18 Market Cap.: 1.90B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 865
Biopharmaceuticals 326
Medical Devices   247

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 11)
  • Tadalafil (PDE5 Selective Inhibitor)
  • Cell Adhesion Molecule Antagonists
  • LFA-1 (LFA-1 Antagonist)
  • IC485 (PDE4 Inhibitor)
Target (Total: 16)
  • PSN357 (Glycogen Phosphlorylase Inhibitor)
  • PSN105/PSN010 (Glucokinase Activators)
  • PSN9301 (Dipeptidyl Peptidase-IV Inhibitor)
  • Novantrone (Mitoxantrone Hydrochloride)
Buyer

n/a
Target
  • Gelclair

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 1)
  • Eli Lilly & Co. (LLY)
Target (Total: 5)
  • Gilead Sciences, Inc. (GILD)
  • Nektar Therapeutics (NKTR)
  • ISIS Pharmaceuticals, Inc. (ISIS)
  • Phase Forward Incorporated (PFWD)
Buyer (Total: 3)
  • Solvay SA (ADR) (SVYSY)
  • GPC Biotech AG (ADR) (GPCB)
  • Seattle Genetics, Inc. (SGEN)
Target (Total: 0)

n/a

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 675 655
Revenue Per Employee 122,488.5 449,674.4
Total Revenue 20.6 74.0
Total Expenses 51.3 95.2
Other Revenue 4.3 7.9
Cost of Revenue 4.6 6.7
SG&A Expense 21.3 36.6
Research & Development 25.3 43.1
Other Operating Expense 0.0 3.0
Operating Income -30.6 -21.2
Unusual Income 0.0 0.9
LT Debt to Capital 106.75 52.32
Fwd P/E 70.77 -58.37
Fwd P/Rev 27.89 5.11
Book Value -17.6 241.5
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Urology > Male Genital Disorders > Penile > Erectile Dysfunction (Impotence)

Target

Focused (): *Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

ICOS Corporation is a biotechnology company that provides therapeutic products to patients. Through Lilly ICOS LLC (Lilly ICOS), its joint venture with Eli Lilly and Company (Lilly), the Company is marketing Cialis (tadalafil) for the treatment of erectile dysfunction. Lilly ICOS is also evaluating tadalafil as a potential treatment in benign prostatic hyperplasia (BPH), hypertension and pulmonary arterial hypertension (PAH). ICOS is working to develop and commercialize potential treatments for other serious unmet medical conditions, such as cancer and inflammatory diseases.

Target

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, ophthalmology and diabetes. In November 2004, the Company launched its flagship anti-cancer product, Tarceva (erlotinib), in the United States, which is a small molecule inhibitor of the epidermal growth factor receptor (HER1/EGFR). Tarceva was approved for sale in the European Union (EU) for the treatment of non-small cell lung cancer (NSCLC) in September 2005. In November 2005, OSI completed its acquisition of Eyetech Pharmaceuticals, Inc. (Eyetech).

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 79.1 83.87
Operating Margin % -156.68 -121.26
Quick Ratio 5.45 3.2
Current Ratio 5.73 4.1
Coverage Ratio -1.18 -0
Total Assets 284.6 676.9
Return on Equity % n/a -190.96
Return on Assets % 7.29 -68.12
Cash+ ST Inv. Per Share 1.63 3.52
Total Debt 278.6 265.0
Total Debt to Equity % 0 109.76
Total Debt to Tangible Equity % n/a 2,747.93
Debt to Asset % 97.90 39.15

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Tadalafil (PDE5 Selective Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cell Adhesion Molecule Antagonists
  
Vascular Disorders  
Primary Pulmonary Hypertension  
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that treat hypertension by increasing level of nitric oxide that help to dilate blood vessels.

Buyer Products:

  • Tadalafil (PDE5 Selective Inhibitor)
  
Dermatology  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • LFA-1 (LFA-1 Antagonist)
  
Endocrinology/Metabolism  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PSN357 (Glycogen Phosphlorylase Inhibitor)
  • PSN105/PSN010 (Glucokinase Activators)
  • PSN9301 (Dipeptidyl Peptidase-IV Inhibitor)
  
Immunology
Autoimmune Disorders  
Multiple Sclerosis (MS)  
Topoisomerase II Inhibitors
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths an enzyme that inhibits the proliferation of cells.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • IC485 (PDE4 Inhibitor)
  • Chemokine Receptor Antagonists
  • Cell Adhesion Molecule Antagonists
  • G-protein Coupled Receptor Antagonists
  • Lipid And Protein Kinase Inhibitors
  • LFA-1 (LFA-1 Antagonist)
  
Infectious Diseases  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Novel Antibiotics (Polyphosphate Kinase Inhibitor)
  
Neurology  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Topoisomerase II Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting a key enzyme involved with cell division.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Oncology
Digestive System  
Pancreatic Cancer  
Metastatic  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Target Products:

  • Tarceva (Erlotinib)
  
Hematology  
Leukemia  
Myeloid  
Acute  
Erythroleukemic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Monocytic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Myeloblastic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Myelogenous (AML)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Promyelocytic (APL)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • Tarceva (Erlotinib)
  • CP-868,596 (Platelet-Derived Growth Factor Receptor Inhibitor)
  • CP 547,632 (VEGFR Inhibitor)
  • OSI-930
  • Avastin (Bevacizumab)/Tarceva (Erlotinib HCl)
  • Novantrone (Mitoxantrone Hydrochloride)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Cell Cycle Checkpoint/DNA Repair Antagonists
  • Monoclonal Antibodies
  • Lipid And Protein Kinase Inhibitors

Target Products:

  • Pegatinib
  • OSI-817
  • OSI-906 (Tyrosine Kinase Inhibitor)
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.

Target Products:

  • Tarceva (Erlotinib)
  
Urology  
Prostate Cancer  
Palliative Agents  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Ophthalmology  
Degenerative Disorders  
Edema  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular edema by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Target Products:

  • Macugen (Pegaptanib Sodium)
  
Macular Degeneration (AMD)  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Target Products:

  • Macugen (Pegaptanib Sodium)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Macugen (Pegaptanib Sodium)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in very early stages of research where no human subject is involved.

Target Products:

  • E10030 (Anti-platelet derived growth factor)
  
Urology  
Male Genital Disorders  
Penile  
Erectile Dysfunction (Impotence)  
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.

Buyer Products:

  • Cialis (Tadalafil)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Tadalafil (PDE5 Selective Inhibitor)
  
Weight Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Target Products:

  • Prosidion Obesity Reserach (Appetite Targets/GPCR Agonist Program/CB-1 Antagonist)
  
Medical Devices  
Medical Supplies  
Treatment  
Wound Management/First Aid  
Drainage/Hydration
Medical devices designed to irrigate, moisturize and remove excess fluids from wounds and wound surface.

Target Products:

  • Gelclair
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 189,562.601 9.80 11.93 3.92 3.97 n/a
GlaxoSmithKline plc (ADR) n/a 157,043.229 14.83 15.19 3.41 3.52 15.15
Buyer
  Pfizer Inc. n/a 189,562.601 9.80 11.93 3.92 3.97 n/a
GlaxoSmithKline plc (ADR) n/a 157,043.229 14.83 15.19 3.41 3.52 15.15
Target
  Pfizer Inc. n/a 189,562.601 9.80 11.93 3.92 3.97 n/a
Roche Holding Ltd. (ADR) n/a 160,954.171 35.71 25.11 5.82 n/a 8.83
GlaxoSmithKline plc (ADR) n/a 157,043.229 14.83 15.19 3.41 3.52 15.15
Novartis AG (ADR) n/a 134,499.467 25.55 17.09 3.66 3.40 3.27
Merck & Co., Inc. n/a 99,844.424 19.66 18.25 4.47 4.55 5.68
Genentech, Inc. n/a 91,244.872 43.18 33.25 9.83 7.97 n/a
AstraZeneca plc (ADR) n/a 84,032.266 14.40 14.31 3.28 3.25 8.43
Amgen, Inc. n/a 83,406.037 28.36 17.21 6.09 5.53 21.30
Eli Lilly & Co. n/a 57,624.986 17.84 16.87 3.76 3.73 4.41
Bristol Myers Squibb Co. n/a 51,547.939 32.52 21.72 2.88 2.67 n/a
Alcon, Inc. n/a 35,310.776 33.50 27.74 7.47 7.26 17.30
Allergan, Inc. n/a 17,753.715 n/a 31.98 6.28 5.75 114.76
Bausch & Lomb Inc. n/a 2,888.473 19.41 82.00 1.23 1.21 5.06
ImClone Systems Incorporated n/a 2,364.976 6.38 18.29 3.49 3.62 3.11
Regeneron Pharmaceuticals, Inc. n/a 1,144.422 n/a -11.09 16.23 16.86 18.32
Pharmion Corporation n/a 974.121 n/a -52.96 4.14 4.05 4.44
GPC Biotech AG (ADR) n/a 955.990 n/a n/a 36.48 n/a 9.48
QLT Inc. (USA) n/a 656.258 n/a 26.12 3.51 3.76 2.03
Onyx Pharmaceuticals, Inc. n/a 495.679 n/a -4.94 1,990.88 1,524.56 3.00
Enzon Pharmaceuticals, Inc. n/a 383.668 n/a 15.14 2.29 2.09 n/a
Ariad Pharmaceuticals, Inc. n/a 346.013 n/a -5.38 371.33 80.48 14.23

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Eli Lilly & Co. n/a 57,624.986 17.84 16.87 3.76 3.73 4.41
Target
  Gilead Sciences, Inc. n/a 28,844.941 38.09 25.99 10.54 9.87 8.74
Nektar Therapeutics n/a 1,200.029 n/a -10.56 6.64 5.93 7.34
ISIS Pharmaceuticals, Inc. n/a 791.707 n/a -18.03 29.08 32.28 n/a
Phase Forward Incorporated n/a 479.432 101.33 48.25 4.80 4.50 9.84
Degussa AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Solvay SA (ADR) n/a 12,857.176 12.95 n/a 1.07 n/a 4.49
GPC Biotech AG (ADR) n/a 955.990 n/a n/a 36.48 n/a 9.48
Seattle Genetics, Inc. n/a 359.739 n/a -9.31 36.93 35.26 3.72

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Eli Lilly & Co. n/a 57,624.986 17.84 16.87 3.76 3.73 4.41
Buyer
  Eli Lilly & Co. n/a 57,624.986 17.84 16.87 3.76 3.73 4.41
Solvay SA (ADR) n/a 12,857.176 12.95 n/a 1.07 n/a 4.49
ImClone Systems Incorporated n/a 2,364.976 6.38 18.29 3.49 3.62 3.11
Target
  Pfizer Inc. n/a 189,562.601 9.80 11.93 3.92 3.97 n/a
Roche Holding Ltd. (ADR) n/a 160,954.171 35.71 25.11 5.82 n/a 8.83
Merck & Co., Inc. n/a 99,844.424 19.66 18.25 4.47 4.55 5.68
Genentech, Inc. n/a 91,244.872 43.18 33.25 9.83 7.97 n/a
Wyeth n/a 68,614.316 16.85 16.22 3.45 3.42 6.53
Eli Lilly & Co. n/a 57,624.986 17.84 16.87 3.76 3.73 4.41
Bristol Myers Squibb Co. n/a 51,547.939 32.52 21.72 2.88 2.67 n/a
Gilead Sciences, Inc. n/a 28,844.941 38.09 25.99 10.54 9.87 8.74
Celgene Corporation n/a 19,017.753 380.36 192.61 24.59 21.36 27.04
McKesson Corporation n/a 16,556.505 20.04 20.21 0.18 0.18 4.02
Merck Serono S.A. (ADR) n/a 13,381.825 19.57 18.91 4.89 4.81 5.54
Nektar Therapeutics n/a 1,200.029 n/a -10.56 6.64 5.93 7.34
ISIS Pharmaceuticals, Inc. n/a 791.707 n/a -18.03 29.08 32.28 n/a
Enzon Pharmaceuticals, Inc. n/a 383.668 n/a 15.14 2.29 2.09 n/a
SGX Pharmaceuticals, Inc. n/a 54.983 n/a -1.79 2.26 2.11 3.86
Schwarz Pharma, Inc. n/a n/a n/a n/a n/a n/a n/a
Archemix Corporation n/a n/a n/a n/a n/a n/a n/a
Sumitomo Chemical Company, Limited n/a n/a n/a n/a n/a n/a n/a
Dipharma Francis Srl n/a n/a n/a n/a n/a n/a n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a
Degussa AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 60.6 344.5 405.1
Other Revenue 16.1 34.4 50.5
Total Revenue 76.7 378.9 455.6
Cost of Revenue 16.0 61.1 77.2
SG&A Expense 80.6 150.6 231.1
Depreciation & Amortization 0.0 21.0 21.0
Research & Development 100.3 173.0 273.3
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 51.5 51.5
Unusual Expense (Income) 0.0 381.2 381.2
Total Expenses 196.8 838.4 1,035.2
Operating Income -120.2 -459.5 -579.6
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 141.5 1.6 143.1
Other, Net 0.0 -3.2 -3.2
Income Before Taxes 21.4 -461.1 -439.8
Income Taxes 0.6 0.0 0.6
Income After Taxes 20.8 -461.1 -440.4
Net Income - Excl. Xord. Items 20.8 -461.1 -440.4
Extraordinary Items 0.0 22.0 22.0
Net Income - Incl. Xord. Items 20.8 -439.1 -418.3
Income Avail. to Common 20.8 -439.1 -418.3
Share Items
Basic Avg. Shares Outstanding 64.6 57.0 121.5
Basic EPS - Excl. Xord. Items 0.32 n/a -3.62
Basic EPS - Incl. Xord. Items 0.32 n/a -3.44
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 65.2 57.0 122.2
F.D. EPS - Excl. Xord. Items 0.32 n/a -3.60
F.D. EPS - Incl. Xord. Items 0.32 n/a -3.42
Balance Sheet
Assets
Cash and Equivalents 21.2 60.2 81.4
ST Investments 85.2 140.5 225.7
Accounts Receivable 22.1 89.6 111.7
Inventory 0.0 63.2 63.2
Prepayments and Advances 0.0 8.6 8.6
Other Current Assets 6.6 10.0 16.6
Current Assets 135.1 372.1 507.2
Accum D&A 0.0 0.0 0.0
PPE, Net 18.3 58.3 76.6
Goodwill & Intangibles 0.0 231.8 231.8
Long Term Investments 126.4 0.0 126.4
Other Assets 0.0 0.0 0.0
Other LT Assets 4.8 14.7 19.5
Total Assets 284.6 676.9 961.6
Liabilities
Accounts Payable 0.0 66.8 66.8
Payable/Accrued 20.7 10.9 31.7
Accrued Expenses 1.4 0.0 1.4
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 0.0 0.0 0.0
Other (Current) Liabilities 1.5 13.0 14.5
Current Liab. 23.6 90.8 114.4
LT Debt 278.6 265.0 543.6
Total LT Debt 278.6 265.0 543.6
Other LT Liab. 0.0 79.7 79.7
Total Liabilities 302.2 435.4 737.7
Shareholders Equity
Common Stock 0.7 0.6 1.2
Additional Paid in Capital 829.5 1,605.6 2,435.1
Retained Earnings -847.4 -1,330.5 -2,177.9
Treasure Stock 0.0 -37.2 -37.2
Other Equity -0.3 3.0 2.7
Total Equity -17.6 241.5 223.9
Total Liab. & Equity 284.6 676.9 961.6
Shares Outstanding 65.5 57.0 122.5
Cash Flow
Operating Cash Flow
CF Net Income 20.8 -439.1 -418.3
CF Depreciation 6.9 35.2 42.1
CF Amortization 0.0 320.3 320.3
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items -6.4 55.6 49.2
Change in Working Capital 0.1 29.4 29.6
Total Cash From Operating Activities 21.3 1.4 22.7
Investing Cash Flow (not calculated)
Capital Expenditures -6.7 -13.9 -20.7
Other Investing Cash Flows -4.3 -180.7 -185.0
Total Cash From Investing Activities -11.1 -194.6 -205.7
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 4.7 -6.1 -1.4
Purchase and Retirement of Debt 0.0 114.2 114.2
Other Financing Cash Flow 0.0 -16.1 -16.1
Total Cash From Financing Activities 4.7 92.1 96.8
Exchange Rate Effects 0.0 -1.5 -1.5
Net Change in Cash 14.9 -102.6 -87.7
Cash Taxes Paid 0.6 0.0 0.6
Cash Interest Paid 5.6 6.0 11.6